Fresenius (ETR:FRE) is walking away from a $4.3 billion merger with U.S. generic drugmaker, Akorn Inc. (NSDQ:AKRX), citing an investigation that found material breaches of FDA data integrity requirements relating to Akorn’s operations.
Fresenius said in a statement that it offered to delay its decision to give Akorn time to compete its own investigation, but Akorn turned the offer down.
Get the full story at our sister site, Drug Delivery Business News.
The post Fresenius abandons $4.3B Akorn merger, citing data integrity probe appeared first on MassDevice.
from MassDevice https://ift.tt/2HnmS7c
Cap comentari:
Publica un comentari a l'entrada